<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842751</url>
  </required_header>
  <id_info>
    <org_study_id>35724-W</org_study_id>
    <secondary_id>1K23HD045386</secondary_id>
    <secondary_id>5U54HD042454</secondary_id>
    <nct_id>NCT00842751</nct_id>
  </id_info>
  <brief_title>Oral T7 Oral Testosterone in Man</brief_title>
  <acronym>Oral T7</acronym>
  <official_title>Pharmacokinetics of a Novel Oral Testosterone Undecanoate Formulation With Concomitant Inhibition of 5alpha-Reductase by Finasteride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test how the body absorbs and processes new forms of oral
      testosterone. Information gained during the study may help develop better forms of
      testosterone therapy in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will be using three drugs: The first, acyline, temporarily turns off the body's production
      of testosterone for about two weeks. Subjects will receive acyline as shots three times over
      a six-week drug administration period. During the time when the body's production of
      testosterone is turned off, we will give testosterone either by itself or with a medication
      called finasteride by mouth twice daily for one week to see how much is absorbed and present
      in the bloodstream after administration. Subjects will go through three one-week study drug
      exposure periods. During two of the three one-week study drug administration periods subjects
      will also take a second medication, finasteride, by mouth twice daily. On the last day of
      each one-week drug administration period, subjects will be admitted to the University of
      Washington General Clinical Research Center overnight for monitoring of your blood
      testosterone levels. There will be 3 overnight visits for this study. This study will allow
      us to determine the absorption of testosterone taken by mouth, and the relative impact of two
      different doses of oral finasteride on testosterone absorption.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Testosterone Concentration</measure>
    <time_frame>0,1,2,4,8,and 12-hour post dose</time_frame>
    <description>Area under the curve of serum testosterone Pharmacokinetic measures time-weighted mean concentration calculated as area under the concentration curve (AUC) divided by time from initiation of dosing for the morning dose and corrected for differences in baseline hormone concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Dihydrotestosterone Concentration</measure>
    <time_frame>0,1,2,4,8,and 12-hour post dose</time_frame>
    <description>Area under the curve of serum dihydrotestosterone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Estradiol Concentration</measure>
    <time_frame>0,1,2,4,8,and 12-hour post dose</time_frame>
    <description>Area under the curve of serum estradiol</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Healthy Males</condition>
  <condition>Male Contraceptive</condition>
  <arm_group>
    <arm_group_label>Testosterone Undecanoate + placebo finasteride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Acyline 300mcg/kg subcutaneous on days 1, 15 and 29 + Testosterone Undecanoate (TU)200mg twice daily, orally for 7 days + placebo finasteride twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone Undecanoate + Finasteride 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300mcg/kg subcutaneous on days 1, 15 &amp; 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 0.5mg twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone Undecanoate + Finasteride 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300mcg/kg subcutaneous on days 1, 15 &amp; 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 1mg twice daily, orally for 7 days during one of the three intervention periods ((First Intervention, Second Intervention or Third Intervention)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>First Intervention (7 days)</intervention_name>
    <description>Acyline 300mcg/kg subcutaneous (days 1, 15 &amp; 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo</description>
    <arm_group_label>Testosterone Undecanoate + placebo finasteride</arm_group_label>
    <other_name>propecia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>First Washout (7 days)</intervention_name>
    <description>Washout of 7 days between each of the 3 treatment arms</description>
    <arm_group_label>Testosterone Undecanoate + placebo finasteride</arm_group_label>
    <other_name>no active drugs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Second Intervention (7 days)</intervention_name>
    <description>Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally</description>
    <arm_group_label>Testosterone Undecanoate + Finasteride 0.5mg</arm_group_label>
    <other_name>propecia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Third Intervention (7 days)</intervention_name>
    <description>Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally</description>
    <arm_group_label>Testosterone Undecanoate + Finasteride 1mg</arm_group_label>
    <other_name>propecia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Second wash-out period</intervention_name>
    <description>Washout of 7 days between each of the 3 treatment arms</description>
    <arm_group_label>Testosterone Undecanoate + Finasteride 0.5mg</arm_group_label>
    <other_name>no active drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males between 18 and 50 years of age

          -  In good health based on normal screening evaluation (consisting of a medical history,
             physical exam normal serum chemistry, hematology, and baseline hormone levels.

          -  Must agree to not participate in another research drug study

          -  Must agree to not donate blood

          -  Must be willing to comply with the study protocol and procedures

        Exclusion Criteria:

          -  Men in poor general health, with abnormal blood results (clinical laboratory tests or
             hormone values)

          -  A known history of alcohol or drug abuse

          -  Participation in a long-term male contraceptive study within the past month

          -  History of bleeding disorders or current use of anti-coagulants

          -  History of sleep apnea

          -  History of major psychiatric disorder

          -  Body mass index &gt; 37

          -  Infertility

          -  Hematocrit &gt; 55 or &lt; 30

          -  PSA &gt;4
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John K Amory, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr</url>
    <description>Dedicated to basic and clinical research focused primarily on the male reproduction system.</description>
  </link>
  <reference>
    <citation>Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996 Dec;81(12):4358-65.</citation>
    <PMID>8954042</PMID>
  </reference>
  <reference>
    <citation>Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997 Aug;82(8):2386-90.</citation>
    <PMID>9253305</PMID>
  </reference>
  <reference>
    <citation>Bhasin S, Bremner WJ. Clinical review 85: Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab. 1997 Jan;82(1):3-8. Review.</citation>
    <PMID>8989221</PMID>
  </reference>
  <reference>
    <citation>Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab. 1996 Oct;81(10):3578-83.</citation>
    <PMID>8855804</PMID>
  </reference>
  <reference>
    <citation>Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000 Aug;85(8):2670-7.</citation>
    <PMID>10946864</PMID>
  </reference>
  <reference>
    <citation>Kelch RP, Jenner MR, Weinstein R, Kaplan SL, Grumbach MM. Estradiol and testosterone secretion by human, simian, and canine testes, in males with hypogonadism and in male pseudohermaphrodites with the feminizing testes syndrome. J Clin Invest. 1972 Apr;51(4):824-30.</citation>
    <PMID>4259253</PMID>
  </reference>
  <reference>
    <citation>Weinstein RL, Kelch RP, Jenner MR, Kaplan SL, Grumbach MM. Secretion of unconjugated androgens and estrogens by the normal and abnormal human testis before and after human chorionic gonadotropin. J Clin Invest. 1974 Jan;53(1):1-6.</citation>
    <PMID>4271572</PMID>
  </reference>
  <reference>
    <citation>Bagatell CJ, Bremner WJ. Androgens in men--uses and abuses. N Engl J Med. 1996 Mar 14;334(11):707-14. Review.</citation>
    <PMID>8594431</PMID>
  </reference>
  <reference>
    <citation>Fosså SD, Opjordsmoen S, Haug E. Androgen replacement and quality of life in patients treated for bilateral testicular cancer. Eur J Cancer. 1999 Aug;35(8):1220-5.</citation>
    <PMID>10615233</PMID>
  </reference>
  <reference>
    <citation>Amory JK, Matsumoto AM. The therapeutic potential of testosterone patches. Expert Opin Investig Drugs. 1998 Dec;7(12):1977-85.</citation>
    <PMID>15991940</PMID>
  </reference>
  <reference>
    <citation>Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000 Dec;85(12):4500-10.</citation>
    <PMID>11134099</PMID>
  </reference>
  <reference>
    <citation>Nieschlag E, Mauss J, Coert A, Kićović P. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Copenh). 1975 Jun;79(2):366-74.</citation>
    <PMID>1173495</PMID>
  </reference>
  <reference>
    <citation>Johnsen SG, Bennett EP, Jensen VG. Therapeutic effectiveness of oral testosterone. Lancet. 1974 Dec 21;2(7895):1473-5.</citation>
    <PMID>4140393</PMID>
  </reference>
  <reference>
    <citation>Daggett PR, Wheeler MJ, Nabarro JD. Oral testosterone, a reappraisal. Horm Res. 1978;9(3):121-9.</citation>
    <PMID>640576</PMID>
  </reference>
  <reference>
    <citation>Amory JK, Bremner WJ. Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab. 2005 May;90(5):2610-7. Epub 2005 Feb 15.</citation>
    <PMID>15713724</PMID>
  </reference>
  <reference>
    <citation>Amory JK, Page ST, Bremner WJ. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. J Androl. 2006 Jan-Feb;27(1):72-8.</citation>
    <PMID>16400081</PMID>
  </reference>
  <reference>
    <citation>Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004 Feb;89(2):503-10.</citation>
    <PMID>14764753</PMID>
  </reference>
  <reference>
    <citation>Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab. 2004 Dec;89(12):5959-65.</citation>
    <PMID>15579744</PMID>
  </reference>
  <reference>
    <citation>Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, Walker SE, Haberer LJ, Clark RV. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007 May;92(5):1659-65. Epub 2007 Feb 13. Erratum in: J Clin Endocrinol Metab. 2007 Nov;92(11):4379.</citation>
    <PMID>17299062</PMID>
  </reference>
  <results_reference>
    <citation>Roth MY, Dudley RE, Hull L, Leung A, Christenson P, Wang C, Swerdloff R, Amory JK. Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride. Int J Androl. 2011 Dec;34(6 Pt 1):541-7. doi: 10.1111/j.1365-2605.2010.01120.x. Epub 2010 Oct 24.</citation>
    <PMID>20969601</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <results_first_submitted>March 21, 2011</results_first_submitted>
  <results_first_submitted_qc>December 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2014</results_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>John Amory</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>5α-reductase</keyword>
  <keyword>androgen</keyword>
  <keyword>dihydrotestosterone (DHT)</keyword>
  <keyword>drug delivery</keyword>
  <keyword>oestradiol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Men age 18-52 in good health were recruited through local newspapers and college campus flyers.</recruitment_details>
      <pre_assignment_details>12 subjects were screened; 11 enrolled (1 did not meet inclusion criteria-abnormal liver function test at baseline and excessive alcohol use). Each subject was administered each of the three treatments over a 6-week period with 1 week of no treatment (wash-out) between each of the treatment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acyline + Testosterone Undecanoate + Placebo Finasteride</title>
          <description>Acyline 300 mcg/kg +Testosterone Undecanoate 200 mg, BID orally + placebo finasteride</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Each subject was administered each of the three treatments over a 6-week period with 1 week of no treatment (wash-out) between each of the treatment period.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum testosterone concentration</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="405" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum dihydrotestosterone concentration</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum oestradiol concentration</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Testosterone Concentration</title>
        <description>Area under the curve of serum testosterone Pharmacokinetic measures time-weighted mean concentration calculated as area under the concentration curve (AUC) divided by time from initiation of dosing for the morning dose and corrected for differences in baseline hormone concentration.</description>
        <time_frame>0,1,2,4,8,and 12-hour post dose</time_frame>
        <population>All participant received all treatments and is, therefore, included in the analysis population for all groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyline +Testosterone Undecanoate + Placebo</title>
            <description>Acyline 300 mcg/kg SC +Testosterone Undecanoate 200 mg, BID orally + Placebo Finasteride</description>
          </group>
          <group group_id="O2">
            <title>Acyline +Testosterone Undecanoate + 0.5mg Finasteride</title>
            <description>Acyline 300 mcg/kg SC + Testosterone Undecanoate 200 mg, BID orally + Finasteride 0.5 mg, BID orally</description>
          </group>
          <group group_id="O3">
            <title>Acyline +Testosterone Undecanoate + 1mg Finasteride</title>
            <description>Acyline 300 mcg/kg SC + Testosterone Undecanoate 200 mg, BID orally + Finasteride 1 mg, BID orally</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Testosterone Concentration</title>
          <description>Area under the curve of serum testosterone Pharmacokinetic measures time-weighted mean concentration calculated as area under the concentration curve (AUC) divided by time from initiation of dosing for the morning dose and corrected for differences in baseline hormone concentration.</description>
          <population>All participant received all treatments and is, therefore, included in the analysis population for all groups.</population>
          <units>ng*hr/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="471" lower_limit="381" upper_limit="581"/>
                    <measurement group_id="O2" value="444" lower_limit="358" upper_limit="551"/>
                    <measurement group_id="O3" value="543" lower_limit="439" upper_limit="671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Dihydrotestosterone Concentration</title>
        <description>Area under the curve of serum dihydrotestosterone</description>
        <time_frame>0,1,2,4,8,and 12-hour post dose</time_frame>
        <population>All participants received all treatment, and is therefore, included in the analysis population for all three treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyline +Testosterone Undecanoate + Placebo</title>
            <description>Acyline 300 mcg/kg subcutaneous (SC) +Testosterone Undecanoate 200 mg, BID orally + Placebo finasteride</description>
          </group>
          <group group_id="O2">
            <title>Acyline + Testosterone Undecanoate + 0.5mg Finasteride</title>
            <description>Acyline 300 mcg/kg SC +Testosterone Undecanoate 200 mg, BID orally + 0.5mg finasteride</description>
          </group>
          <group group_id="O3">
            <title>Acyline + Testosterone Undecanoate + 1mg Finasteride</title>
            <description>Acyline 300 mcg/kg SC +Testosterone Undecanoate 200 mg, BID orally + 1mg finasteride</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Dihydrotestosterone Concentration</title>
          <description>Area under the curve of serum dihydrotestosterone</description>
          <population>All participants received all treatment, and is therefore, included in the analysis population for all three treatment groups.</population>
          <units>ng*hr/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154" lower_limit="125" upper_limit="190"/>
                    <measurement group_id="O2" value="118" lower_limit="96" upper_limit="146"/>
                    <measurement group_id="O3" value="125" lower_limit="102" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Estradiol Concentration</title>
        <description>Area under the curve of serum estradiol</description>
        <time_frame>0,1,2,4,8,and 12-hour post dose</time_frame>
        <population>All participants received all treatment, and is therefore, included in the analysis population for all three treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyline +Testosterone Undecanoate + Placebo</title>
            <description>Acyline 300 mcg/kg SC + Testosterone Undecanoate 200 mg, twice daily (BID) orally + placebo finasteride</description>
          </group>
          <group group_id="O2">
            <title>Acyline + Testosterone Undecanoate + 0.5mg Finasteride</title>
            <description>Acyline 300 mcg/kg SC +Testosterone Undecanoate 200 mg, BID orally + 0.5mg finasteride</description>
          </group>
          <group group_id="O3">
            <title>Acyline +Testosterone Undecanoate + 1mg Finasteride</title>
            <description>Acyline 300 mcg/kg SC +Testosterone Undecanoate 200 mg, BID orally + 1mg finasteride</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Estradiol Concentration</title>
          <description>Area under the curve of serum estradiol</description>
          <population>All participants received all treatment, and is therefore, included in the analysis population for all three treatment groups.</population>
          <units>ng*hr/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="6.4" upper_limit="9.7"/>
                    <measurement group_id="O2" value="6.5" lower_limit="5.2" upper_limit="8.0"/>
                    <measurement group_id="O3" value="7.2" lower_limit="5.8" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>First Intervention</title>
          <description>Acyline 300mcg/kg subcutaneous on days 1, 15 &amp; 29 + Testosterone Undecanoate 200 mg, twice daily, orally + Finasteride placebo, twice daily, orally</description>
        </group>
        <group group_id="E2">
          <title>Second Intervention</title>
          <description>Acyline 300mcg/kg subcutaneous on days 1, 15 &amp; 29 + Testosterone Undecanoate 200 mg, BID orally + Finasteride 0.5mg, twice a day, orally</description>
        </group>
        <group group_id="E3">
          <title>Third Intervention</title>
          <description>Acyline 300mcg/kg subcutaneous on days 1, 15 &amp; 29 + Testosterone Undecanoate 200 mg, twice daily orally + Finasteride 1mg, twice a day, orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upset Stomach &amp; Reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Testicular Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Amory, MD</name_or_title>
      <organization>University of Washington, Dept. of Medicine</organization>
      <phone>(206) 616-1727</phone>
      <email>jamory@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

